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An Approach to the Determination of the
Relative Potencies of Chemical Agents
During the Stages of Initiation and
Promotion in Multistage
Hepatocarcinogenesis in the Rat
by Henry C. Pitot* and Harold A. Campbell*
Thepotency ofcarcinogenic agents in elicitingneoplastic lesionshaslongbeenaconcernofinvestigators
in the field of oncology. This paper describes a method, based on quantitative stereologic calculations, to
estimate the relative potency of chemicals as initiating and/or promoting agents. The parameters defined
in this paper are: (a) Initiation index = no. foci induced x liver' x [mmole/kg body weight]-'; and (b)
Promotion index = V1V, x mmole-' x wk-'. These parameters have been calculated for a number of
chemical agents, based both on data from this laboratory and others published in the literature. Neither
parametervaried significantly with the dose oftwo different initiatingagents used in this study. Therange
of promotion indices extended over more than eight orders of magnitude, whereas that of the initiation
indices was much less variable. Such parameters may be useful as quantitative estimates of the potency
of hepatocarcinogenic agents not only in rodents, but potentially in quantitative risk estimations in the
human.
Introduction
Themultistage nature ofcarcinogenesis has nowbeen
demonstrated in a number of histogenetic systems in
several species (1-3). Implicit in such a concept is that
carcinogenic agents can act principally or exclusively at
one or all of the definable stages in the carcinogenic
process. Thus, complete and incomplete carcinogens
have been defined as agents capable of acting at all
stages ofcarcinogenesis oronly atthe stage ofinitiation,
respectively (3). Promoting agents are considered to
effect only the stage of promotion, although they may
simulate the action ofcomplete carcinogens through the
promotion of spontaneously or fortuitously initiated
cells (3).
A number of methods have been used to determine
the relative carcinogenic potencies of chemical agents
in rodents (4); however, few have attempted to quan-
titate the potency of an agent with respect to its action
on a specific stage ofcarcinogenesis (5). Multistage car-
cinogenesis has been studied most extensively in the
mouse epidermis and in the rat liver (3,6). In both of
these systems, at least three distinct stages have been
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identified and, atleastfortheliver, definitionsproposed
(7,8). These stages have been termed initiation, pro-
motion, and progression. Although studies on the skin
have had a much longer history, the liver system offers
the advantage, at least for quantitative studies, ofthe
identification and enumeration ofthe early clonal prog-
eny of initiated cells (3,9). This characteristic provides
the process of multistage hepatocarcinogenesis in the
rat with the potential for quantitating the potencies of
agents in their action at each of the stages of hepato-
carcinogenesis. Methods for determining such param-
eters for the stages ofinitiation and promotion in hepa-
tocarcinogenesis in the rat are presented in this paper.
Methods
The data used for the derivation of the parameters
described inthispaperwere obtainedlargelyfromstud-
ies carried out in this laboratory on the model described
by us in 1978 (10). This model, like that ofPeraino and
his associates (11), allows forthe administration ofnon-
necrogenic doses of an initiating agent, which may be
a complete or incomplete carcinogen. For the most
reproducible and distinctive quantitation of an agent's
initiating potency, it is important that the dose of the
initiatingagentadministeredresultinayieldofenzyme-
altered foci (11), which can be accurately quantitatedPITOT AND CAMPBELL
after their complete expression by administration of a
promoting agent (12). The validity of this approach is
supported by the finding from at least three different
laboratories that each focus is clonal (13-15). The tech-
niques for tissue preparation and quantitation of
enzyme-altered foci have been previously described
from this laboratory (10). A critical factor in such cal-
culations with respect to the number ofenzyme-altered
foci is that quantitation in three rather than in two
dimensions be employed, for reasons previously pre-
sented by this laboratory (16). On the other hand, for
the determination ofthe parameterinvolvingthe poten-
cy of promoting agents, the area ofthe transections of
enzyme-altered foci seen in two dimensions on a micro-
scopic slide, given as a percentage of the total area of
the slide (mm2/cm2), is identical with the volume per-
centage measurements in three dimensions.
Arepresentative computeroverlayofthreeserialsec-
tions stainedrespectivelyfor -y-glutamyltranspeptidase
(GGT), canalicular ATPase (ATPase), and glucose-6-
phosphatase (G6Pase) is presented in Figure 1. It is
from such preparations, with the use of computer or
hand calculations, that one may determine the param-
eters described in this paper. Furthermore, although
three markers are used in this figure, recent evidence
(17) in confirmation of earlier studies (10,18) indicates
thatonlytwo ofthesemarkers areneeded to score more
than 90% of the enzyme-altered foci, as long as one of
the markers is GGT. Not used in this study is an even
G6Pase
ATPase
GGT
more efficient marker, the placental form ofglutathione
transferase (GST-P) (19). Thismarkeriscapableofscor-
ing more than 90% of quantifiable enzyme-altered foci
in rat liver as determined by quantitative stereologic
methods (17). However, with some promoting agents,
such as those inducing proliferation of hepatic peroxi-
somes (20), ATPase and G6Pase are needed in combi-
nation to score the same proportion, since many fewer
nodules promoted by these agents express GST-P or
GGT. Therefore, in order to score the maximal number
offoci under all known conditions, GGT or, preferably,
GST-P, together with either ATPase or G6Pase or a
comparable marker, would be the preferred combina-
tion. Since identification of GST-P is carried out by an
immunohistochemical procedure on acetone- or formal-
in-fixed tissues, another marker with the biological
characteristics ofeitherATPase or a G6Pase, scored by
similar techniques, would obviate the need for frozen-
section technology.
Relative Potencies of Initiating and
Promoting Agents-Initiation and
Promotion Indices
A number ofinvestigators (5,21) have classified some
chemicals on the basis of their activity in promoting
enzyme-altered foci and nodules after initiation with
diethylnitrosamine (DEN) by quantitation of the num-
0
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FIGURE 1. Artist's redrawing of a computer graphic plot ofthree serial frozen sections of liver from an animal treated with a single dose of
diethylnitrosamine 24 hrfollowing a 70% partial hepatectomy and subsequently placed on a diet containing 0.05% phenobarbital for6months
(10). Each section is stained for one ofthe enzymes seen in the figure, which was generated by techniques previously described (22).
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ber (in mm2) of transections/cm2 and area of the focal
lesions as end points. We have developed a system
based on the quantitative stereologic determination of
the values of both number of enzyme-altered foci per
liverand volume percentage occupied bythesefoci (22).
As we havepreviouslypointed out, such athree-dimen-
sionalcalculationiscriticalincomparative studies, since
it takes into account the differing sizes of the lesions
that occur in most model systems (16).
We have based the calculations for determining the
potency ofa chemical as an initiating and/or promoting
agent on the biological characteristics of each of these
processes. As has been pointed out by a number of
authors (2,3,6,23,24), initiation is a process occurring
within a single cell, with this initiated cell conferring
its altered state to all ofits progeny. One definition of
initiation is as follows:
Initiation is that process occurring in a cell and resulting from
the action ofa chemical, physical, or biological agent that alters in
an irreversible manner the heritable structure(s) ofthe cell. Such
an initiated cell has the potential of developing into a clone of
neoplastic cells (8).
In multistage hepatocarcinogenesis there is now
ample evidence that each enzyme-altered focus is the
clonal progeny of a single cell (13-15) that exhibits
essentially all of the characteristics expected of an ini-
tiated cell population (3,25). Thus, for the purposes of
these calculations, we have equated the number of
enzyme-altered foci, as determined by three indepen-
dent biochemical parameters (GGT+, ATPase-, and
G6Pase- phenotypes) withthenumberofinitiated cells.
In this way one may relate the number ofinitiated cells
to the dose of the initiating agent, since the latter is
given only as a single dose in this and many othermodel
systems ofhepatocarcinogenesis (26). We have, there-
fore, defined the initiation index as follows:
Initiation index = no. foci induced x liver'
x [Inmole/kg body weight]-'
The number of foci induced are those found in the
liver ofthe animal that has been promoted with a max-
imally effective dose ofpromotingagent (12) forat least
the time required to express all initiated cells quanti-
fiable by the marker(s) used to score such clones minus
the number ofenzyme-altered foci occurring in animals
notreceivingthe initiating agentbutpromotedwiththe
same dose of promoting agent. This method thus cor-
rectsforlevels ofspontaneously orfortuitouslyinitiated
cells, whose formation is independent of the initiating
agent administered. A calculation ofthe initiatingindex
should be made from doses of the initiator that do not
induce cell death or other severe toxicity, as every cell
in the exposed population should have the same chance
to become initiated.
The evaluation ofthe promoting potency ofan agent
is based on ourknowledge ofthe nature ofthebiological
effect of promoting agents as determined from experi-
ence in those systems in vivo in which multistage car-
cinogenesis is best understood, namely, the mouse epi-
dermis and the rat liver. On the basis ofthese systems,
one may define promotion as follows:
Promotion is that stageinthe naturalhistoryofneoplasticdevel-
opment which, if existent, is characterized by (a) the reversible
expansion of the initiated cell population and (b) the reversible
alteration of genetic expression (8).
In this definition, the emphasis is on reversibility, a
biologicalcharacteristic ofpromotioninallknownmodel
systems of multistage hepatocarcinogenesis in the rat
(26) and in most, if not all, such systems in the mouse
epidermis (27). Numerous studies have demonstrated
that promoting agents cause a selective increase in the
numbers of the cells within enzyme-altered foci in rat
liver (9,26,27), and all known promoting agents are
known to alter gene expression in normal cells in a
reversible manner (3,6,28,29). The phrase "ifexistent"
is employed in this definition, since there are numerous
examples, in chemical and physical as well as biological
carcinogenesis, resulting from direct application ofthe
carcinogenic agent with no demonstrable reversible
stages. Presumably, under such conditions the stage of
initiationisfollowedimmediatelybythatofprogression,
the final irreversible stage ofmultistage carcinogenesis
in which malignant neoplasms occur (27,30).
On the basis of such operational knowledge of the
characteristics of promoting agents, we have defined
the following parameter:
Promotion index = Vfhr IVc x mmole-' x wk-1
where Vfis thetotal volume occupied byallthe enzyme-
altered foci in the liver ofanimals treated with the test
agent, and V, is the total volume ofthe enzyme-altered
foci in the control animals, which have only been initi-
ated. These volumes are expressed as a percentage of
the total volume or weight of the liver. The milimoles
of the promoting agent administered per week are
determined eitherdirectly, ifameasured amount ofthe
agent is administered per day, week, or month, or as
that consumed in an average food intake of 20 g/day
(31). Since the volume occupied by the foci is directly
related to cell number, the measurement of effective-
ness ofapromoting agent may, therefore, be related to
its ability to stimulate selectively or to allow the rep-
lication ofthe promoter-dependent progeny ofinitiated
cells (32,33). The correction for the volume percentage
of enzyme-altered foci in animals that have only been
initiated allows for the effect of uncontrolled endoge-
nous orexogenous promotingagents inthe experiment.
Unfortunately, such a correction does not take into
account any possible synergy between the test agent
and uncontrolled promoting activities, such as dietary
factors and endogenous hormones. Unlike the initiation
index, which is determined afterpromotion for aperiod
allowing the demonstration of the progeny of all initi-
ated cells, the promotion index, although usually deter-
mined after 6 months oftreatment with the promoting
agent, maybedetermined atothertimeintervalsduring
carcinogenesis as well. However, promotion indices
must be calculated at levels of administration of the
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promoting agent that exceed the threshold or no-effect
levels of the agent and do not exceed the levels that
resultin amaximal effect (12). Therefore, itisimportant
to determine the dose-response characteristics of the
promoting agent prior to the evaluation of a promotion
index for the compound.
Table 1 (34-41) shows some representative initiation
and promotion indices taken both from studies reported
in this paper and from those described earlier in the
literature from this and other laboratories. In those
values estimated from the literature and not from work
in this laboratory, some assumptions had to be made,
since the format ofthe experiments was somewhat dif-
ferent from those in the model used in this and other
studies (34,36) from this laboratory. In the studies
reported by Malvaldi et al. (40) onthe promotive effects
ofthiobenzimide, the areaofGGT+ foci wasusedinstead
ofthe volume, but, as has been pointed out earlier (16),
these two parameters are identical for the purposes of
calculating promotion indices. Similarly, the promotion
indices for 3'-methyl-4-dimethylaminoazobenzene (3'-
Me-DAB) and N-2-fluorenylacetamide were calculated
from the area of GGT+ foci as presented in the work
by Tsuda et al. (41). In this latter study, initiation was
accomplished by a single IP dose of DEN (200 mg/kg).
Two weeks later, rats were fed these agents in the diet
for a period of6 weeks, at which time the area ofGGT+
foci was determined. This study described many other
compounds tested in a similar manner for which pro-
motion indices could be calculated by the techniques
described inthis paper. Thepromotion indexfor4-dime-
thylaminoazobenzene (DAB) was calculated from the
volume percentage ofthose foci scored as GGT+ in rats
initiated by the administration ofN-nitrosodiethanola-
mine in the drinking water (2000 ppm) for 6 weeks fol-
lowed by a 2-week interval in which no carcinogen was
administered, followed by the feeding of DAB in the
diet (0.16%). In that study (39), foci were scored either
as GGT+ or ATPase, and the value in the table was
that ofGGT+ enzyme-altered foci. The promotion index
calculated from the ATPase- foci was 8.0.
It is of interest that, where values for initiation and
promotion indices were calculated for the same com-
pound in two different strains of rats, the values seen
intheSprague-Dawleyanimals werealwayshigherthan
those of the F344 strain. On the other hand, when ini-
tiation indices for DEN and (7,12-dimethylbenz[a]an-
thracene (DMBA) are calculated over a range of doses
(Table 2), the values do overlap, although animals of
the Sprague-Dawleystrain appeartoexhibit higherval-
ues than those of the F344 strain. For both of these
intitiating agents in any one strain, however, the values
ofthe initiation indices within a single rat strain do not
vary a great deal. Furthermore, as shown in Table 3,
the promotion index is relatively stable over a wide
range ofdoses oftwo different initiating agents, DMBA
and DEN. The relatively high value seen at the 1.0 mg/
kg dose of DEN is unexplained at the moment, but
virtually all of the other values are relatively close to
one another. Even in studies done in different labora-
tories of two closely related compounds, DAB and 3'-
Me-DAB (Table 1), the calculated promotion indices
from the available data are quite similar. As yet there
are insufficient data to calculate promotion indices as a
function of the concentration of the promoting agent
administered, as only one or a few values have been
available on the effective portion of the curve (12).
Discussion
At the present time, the determination ofthe carcin-
ogenic activity of a chemical is basically a qualitative
analysis. At the regulatory level ofgovernmental agen-
cies, no attempt is made to distinguish the action of
chemical agents in the various stages ofcarcinogenesis;
rather, all agents are assumed to be complete carcino-
Table 1. Relative potencies for initiation and promotion of hepatocarcinogenic agents in the rat.
Agenta Initiation indexb Promotion indexb Reference
Proflavin 6.9 x 10_ (34)
DMBA 1.6 x 105 (F344)c (35)
DEN 7.2 x 105 (F344) 1.5 (F344) (35)
10.5 x 106 (S-D)d (35)
Butylated hydroxytoluene 0.3 (S-D) (34)
l'OH-Safrole 3.1 x 103 950 (36)
TCDD 0.0 (F344) 1.0 x 106 (F344) (35)
2.8 x 107 (S-D) (37)
Wy 14,643 63 (38)
DAB 20 (39)
3'-Me-DAB 17 (41)
Thiobenzamide 60 (40)
Phenobarbital 0.0 (F344) 6 (F344) (34,35)
75 (S-D) Unpublished observations
N-2-Fluorenylacetamide 927 (41)
aAbbreviations: DMBA, 7,12-dimethyl[a]anthracene; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; DAB, 4-dimethylaminoazobenzene; 3'-Me-
DAB, 3'-methyl-4-dimethylaminoazobenzene.
bReferences to previously published studies are indicated in the reference column. The reader is referred to the text for details of the
calculations.
CF344: Fischer F344/NHsdBR strain rats.
dS-D: Sprague-Dawley (SD)BR strain rats.
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Table 2. Initiation indices as a function of dose of initiating
agent in the rat.a
Initiation index
Initiating agent Dose, mg/kg F344 Sprague-Dawley
DEN 0.01 4.3 x 106
0.1 6.0 x 106
0.3 5.1 x 105
1.0 1.7 x 106 1.4 x 106
2.0 0.7 x 106
3.0 4.4 x 105
5.0 0.7 x 106
10.0 2.2 x 105
DMBA 0.1 3.5 x i05
1.0 1.7 x 105
10.0 0.5 x 105
30.0 0.9 x 105
aThe format for the studies has been described (35). See footnotes
of Table 1 for abbreviation key.
Table 3. Promotion index (PI) of phenobarbital in F344 female
rats at various doses of the initiating agents DMBA and DEN.a
Initiating agent Dose, mg/kg Promotion index
DMBA 1.0 5
10 10
30 4
DEN 0.3 4
1.0 26
3.0 5
10.0 6
30.0 5
aSee footnotes ofTable 1 for procedural details and abbreviations.
gens ifthey exhibit any significant carcinogenic activity
(42,43). Studies ofmultistage carcinogenesis in a num-
ber of different tissues in laboratory animals over the
past several decades have demonstrated that such an
assumption, in a significant number ofinstances, is not
warranted (1-3). The reversible nature ofthe stage of
tumor promotion, which has now been clearly shown in
the best-studied multistage carcinogenesis models,
those of mouse epidermis (6,44) and rat liver (9,26),
demonstrates that no matter what mechanism is
involved, the presence ofa no-effect level is inherent in
the characteristic of reversibility, and additivity may
occur only in a relatively narrow window of the dose-
response curve. Since risk estimations in the human
always involve quantitative parameters, ifanimal stud-
ies are to be utilized in such determinations, then quan-
titation ofthe relative efficiencies ofchemicals in animal
systems should be very important for quantitative risk
estimations across species lines.
Until recently, most methods for the determination
of relative carcinogenic potencies of chemical agents
related dose of the agent, either total dose or a dose
rate, to some time function involving the yield or some
fraction thereof ofmalignant neoplasms. An early pro-
posal by Iball (45) related the carcinogenic potency of
a chemical to the percentage of animals developing
tumors divided by the latent period in days x 100. By
this straightforward analysis, potent carcinogens usu-
ally induce many tumors in a relatively short
time,whereas weak carcinogens induce fewer neo-
plasms, and then, only after a prolonged latent period.
Barr's review (4) of various calculations used to deter-
mine carcinogenic potency refers to many different pro-
cedures that have been used in the past, both in exper-
imental circumstances and also from regulatory agen-
cies. Lutz and his associates (46) have developed equa-
tions relating the efficacy with which chemicals
stimulate DNA synthesis and DNA binding in relation
to their carcinogenic potencies. These calculations have
been applied with some success to the prediction ofcar-
cinogenic potency for hepatocarcinogens in experimen-
tal situations. Parodi et al. (47) related the induction of
preneoplastic nodules during hepatocarcinogenesis to
the carcinogenic potencies ofa variety ofdifferent com-
pounds, most ofwhich values were taken from studies
in the literature.
Several studies, including some from our own labo-
ratory (12,18,48), have demonstrated that the dose-
response curves forinitiation ofenzyme-altered foci are
different from those of promoting agents in that the
latter exhibit no-effect dose rates of promotion admin-
istration. Furthermore, a maximal effect of promoting
agents is seen in the absence of toxicity, presumably
resulting from the promotion ofall foci developing from
a finite number ofinitiated cells (12). Since it is impos-
sible to prove unequivocally the presence or absence of
a threshold under any circumstances involvingmultiple
data points, despite the graphic appearance ofthe dose-
responserelationship, theultimateinterpretation ofthe
data will depend on the presumed or observed mecha-
nism ofthe agent in question. Initiation has been shown
again and again to be an irreversible phenomenon in
those systems in which this stage can be clearly distin-
guished (3,6). On the other hand, as described earlier,
both inthe liverand the skin systemsinwhichthe stage
of promotion has been clearly defined and delineated,
this stage is reversible. Thus, agents acting exclusively
or even predominantly at this stage of carcinogenesis
would be expected to exhibit threshold levels, as has
been shown for numerous drugs and chemical agents
exhibitingreversible effects in avarietyofsystems(49).
The use ofthe number offocal lesions, each developing
clonally from a presumed initiated cell, as a measure of
the effectiveness of initiation is quite logical. The rel-
ative reproducibility ofeven the limited amount ofdata
seen in this report would support this approach as a
measure of the potency of a compound as an initiating
agent in multistage hepatocarcinogenesis in the rat.
Promotion indices are apparently more variable than
those forinitiation (Table 1), as might be expected from
the known environmentalmodulationofthis stage (2,3).
Despite this, promotion indices for the same or related
compounds as studied in different laboratories are quite
similar, as shown, for example, in Table 1 for DAB and
3'-Me-DAB (39,41). Another example is the similarity
of the promotion index for phenobarbital as noted in
Tables 1 and 3, and that of 7.0 as calculated from the
data of Tsuda et al. (41) in the F344 strain from that
laboratory. Although this report deals only with the
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enumeration of enzyme-altered foci under the limits of
identification used previously by this laboratory (22),
recent studies (50) suggest that with different markers
it may be possible to identify many more initiated cells.
It will be ofinterest to determine inthe future whether
the inclusion of such presumably initiated hepatocytes
inthe calculations willrelate to the potency ofinitiating
agents in this system.
Unlike the initiation indices noted in Table 1, the
range of promotion indices extends over almost eight
orders of magnitude. Previous attempts to relate car-
cinogenic potencies also indicated an extremely wide
range ofpotencies for a large number ofchemicals (51).
If one correlates these data with estimations from the
literature, one conclusion is that the promotion index is
more important than the initiation index for determin-
ing the overall carcinogenic potency ofa chemical. It is
also of interest that in all cases in which initiation or
promotion indices were calculated for the same com-
pound in two different strains of rats, the Sprague-
Dawley strain always had a higher value. This finding
is supported somewhat by the recent studies ofRussell
et al. (52), who compared initiation by DEN and pro-
motion by phenobarbital in the same two strains ofani-
mals. Their studies also showed a greater sensitivity to
these two compounds in the Sprague-Dawley strain.
Further studies are needed to determine exactly how
consistent promotion indices are under various exper-
imental conditions of diet, sex, age, etc., since all of
these factors have been shown to affect the stage of
promotion in multistage carcinogenesis (2,3,23,24).
Clearly, the dose response affects the promotion
index, because no valid index can be calculated below
the threshold level ofthe agent, and calculation ofpro-
motion indices after a maximal effect ofthe promoting
agent has been obtained will lead to spuriously low
results. Thus, meaningful promotion indices that can be
compared from laboratory to laboratory and even from
experiment to experiment must be calculated on the
relatively linear portion of the dose-response curve.
Similarly, initiation indices mustbe calculated from val-
ues on the increasing, relatively linear portion of the
dose-response curve (48) in order to eliminate possible
artifacts due to cell death, toxicity, etc.
Although the potency parameters proposed in this
paper are limited to hepatocarcinogenic agents, other
systems are now being developed in which the clonal
progeny of initiated cells may be quantitatively deter-
mined and in which quantitation ofthe total promoted
cell population is possible. Analogous calculations of
potencies may already be applicable, in part, at least,
tosuchtissues astheepidermis (53), pancreas (54), lung
(55), thyroid (56,57), brain (58,59), and mammary gland
(60,61). Such quantitative calculations, based on a
knowledge ofthe characteristics ofthese two stages of
carcinogenesis, may be helpful in determining quanti-
tative parameters useful in risk assessment in the
human being.
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